Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Common Equity (2021 - 2025)

Kiniksa Pharmaceuticals International (KNSA) has disclosed Common Equity for 5 consecutive years, with $567.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Common Equity rose 29.46% year-over-year to $567.6 million, compared with a TTM value of $567.6 million through Dec 2025, up 29.46%, and an annual FY2025 reading of $567.6 million, up 29.46% over the prior year.
  • Common Equity was $567.6 million for Q4 2025 at Kiniksa Pharmaceuticals International, up from $535.4 million in the prior quarter.
  • Across five years, Common Equity topped out at $567.6 million in Q4 2025 and bottomed at $153.5 million in Q2 2022.
  • Average Common Equity over 5 years is $372.5 million, with a median of $408.4 million recorded in 2023.
  • The sharpest move saw Common Equity plummeted 38.59% in 2022, then soared 168.19% in 2023.
  • Year by year, Common Equity stood at $185.0 million in 2021, then soared by 114.09% to $396.1 million in 2022, then rose by 10.78% to $438.8 million in 2023, then fell by 0.09% to $438.4 million in 2024, then rose by 29.46% to $567.6 million in 2025.
  • Business Quant data shows Common Equity for KNSA at $567.6 million in Q4 2025, $535.4 million in Q3 2025, and $495.0 million in Q2 2025.